# Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

> **NCT07570966** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 217 (estimated)

## Conditions studied

- Advanced HR+/HER2- Breast Cancer
- Advanced CCNE1-amplified Solid Tumors
- Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** ERW316
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT07570966
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2031-08-01
- **Final completion:** 2031-08-01
- **Target enrollment:** 217 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570966, "Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07570966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*